HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Targeting RAS signaling pathways in juvenile myelomonocytic leukemia.

Abstract
The RAS proteins function as fundamental signaling switches that control normal cell growth and differentiation. Deregulated activation of RAS-dependent signaling pathways constitutes a potent mechanism of malignant cell transformation. Juvenile myelomonocytic leukemia (JMML) is a rapidly fatal myeloproliferative disorder of early childhood for which no effective treatment other than hematopoietic stem cell transplantation is currently available. Many aspects of JMML pathobiology are linked to deregulated RAS signaling. Hence, targeting RAS or its interactors on a molecular level is a promising strategy in the development of novel rational therapies for this menacing disease. Here we give an overview of current concepts on the pathogenesis of JMML, present important aspects of cellular RAS biology that can be exploited for pharmacologic manipulation, and discuss mouse models that have greatly advanced our understanding of the role RAS plays in JMML. In addition, we review recent approaches to develop agents that interfere with the RAS network at the level of the granulocyte-macrophage colony-stimulating factor receptor, posttranslational RAS processing (prenylation and endoprotease cleavage), RAF serine/threonine kinase, MEK mitogen-activated protein kinase, and target of rapamycin activity. Preclinical and clinical data of these pharmaceuticals in JMML and other myeloid malignancies is discussed.
AuthorsChristian Flotho, Christian Kratz, Charlotte M Niemeyer
JournalCurrent drug targets (Curr Drug Targets) Vol. 8 Issue 6 Pg. 715-25 (Jun 2007) ISSN: 1873-5592 [Electronic] United Arab Emirates
PMID17584027 (Publication Type: Journal Article, Review)
Chemical References
  • Antineoplastic Agents
  • ras Proteins
Topics
  • Animals
  • Antineoplastic Agents (pharmacology, therapeutic use)
  • Child
  • Disease Models, Animal
  • Drug Delivery Systems
  • Humans
  • Leukemia, Myelomonocytic, Acute (drug therapy, pathology)
  • Leukemia, Myelomonocytic, Chronic (drug therapy, pathology)
  • Mice
  • Signal Transduction (drug effects, physiology)
  • ras Proteins (drug effects, metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: